keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase and breast cancer

keyword
https://www.readbyqxmd.com/read/28821472/surgical-findings-and-outcomes-in-premenopausal-breast-cancer-patients-undergoing-oophorectomy-a-multicenter-review-from-the-fellows-pelvic-research-network
#1
Lara F B Harvey, Vandana G Abramson, Jimena Alvarez, Christopher Destephano, Hye-Chun Hur, Katherine Lee, Patricia Mattingly, Beau Park, Carolyn Piszczek, Farinaz Seifi, Mallory Stuparich, Amanda Yunker
STUDY OBJECTIVE: Since publication of the Suppression of Ovarian Function Trial (SOFT) data, some women with premenopausal breast cancer have been recommended to undergo bilateral oophorectomy to facilitate breast cancer treatment with aromatase inhibitors. These women may be at higher risk of occult abdominal pathology than the general population. Our objective is to describe the procedures performed, intra-abdominal findings, and surgical pathology of this population. DESIGN: Multi-center retrospective chart review...
August 15, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/28805983/challenges-of-measuring-accurate-estradiol-levels-in-aromatase-inhibitor-treated-postmenopausal-breast-cancer-patients-on-vaginal-estrogen-therapy
#2
Polly Niravath, Raksha Bhat, Mohamed Al-Ameri, Ahmed AlRawi, Claudette Foreman, Meghana V Trivedi
Breast cancer patients who are taking adjuvant Aromatase Inhibitor (AI) therapy typically have extremely low estradiol levels, which are undetectable by routine clinical laboratories. Thus, it becomes difficult to assess the safety of interventions such as low-dose vaginal estrogen, which may increase estradiol levels. In this study, we aimed to assess the utility of enzyme-linked immunosorbent assay (ELISA) to measure low estradiol concentrations in breast cancer survivors on AI therapy treated with either vaginal estrogen or lubricant for atrophic vaginitis as a part of clinical trial...
August 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28801846/vascular-function-in-breast-cancer-survivors-on-aromatase-inhibitors-a-pilot-study
#3
Anne Blaes, Heather Beckwith, Natalia Florea, Robert Hebbel, Anna Solovey, David Potter, Douglas Yee, Rachel Vogel, Russell Luepker, Daniel Duprez
PURPOSE: Aromatase inhibitors (AI) have been shown to reduce breast cancer-related mortality in women with estrogen positive (ER+) breast cancer. The use of AIs, however, has been associated with higher rates of hypertension, hyperlipidemia, and cardiovascular (CV) events. METHODS: A cross-sectional study of 25 healthy postmenopausal women and 36 women with curative intent breast cancer on an AI was performed to assess endothelial dysfunction, an indicator of risk for CV events...
August 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28799536/estrogen-receptor-esr1-mutation-in-bone-metastases-from-breast-cancer
#4
Stephan Bartels, Matthias Christgen, Angelina Luft, Sascha Persing, Kai Jödecke, Ulrich Lehmann, Hans Kreipe
Activating mutations of estrogen receptor α gene (ESR1) in breast cancer can cause endocrine resistance of metastatic tumor cells. The skeleton belongs to the metastatic sides frequently affected by breast cancer. The prevalence of ESR1 mutation in bone metastasis and the corresponding phenotype are not known. In this study bone metastases from breast cancer (n=231) were analyzed for ESR1 mutation. In 27 patients (12%) (median age 73 years, range: 55-82 years) activating mutations of ESR1 were detected. The most frequent mutation was p...
August 11, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/28795252/ipet-study-an-flt-pet-window-study-to-assess-the-activity-of-the-steroid-sulfatase-inhibitor-irosustat-in-early-breast-cancer
#5
Carlo Palmieri, Richard Szydlo, Marie Miller, Laura Barker, Neva H Patel, Hironobu Sasano, Tara Barwick, Henry Tam, Dimitri Hadjiminas, Jasmin Lee, Abeer Shaaban, Hanna Nicholas, R Charles Coombes, Laura M Kenny
BACKGROUND: Steroid sulfatase (STS) is involved in oestrogen biosynthesis and irosustat is a first generation, irreversible steroid sulfatase inhibitor. A pre-surgical window-of-opportunity study with irosustat was undertaken in estrogen receptor-positive (ER+) breast cancer to assess the effect of irosustat on tumour cell proliferation as measured by 3'-deoxy-3'-[18F] fluorothymidine uptake measured by PET scanning (FLT-PET) and Ki67. METHODS: Postmenopausal women with untreated ER+ early breast cancer were recruited, and imaged with FLT-PET at baseline and after at least 2 weeks treatment with irosustat, 40 mg once daily orally...
August 9, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28794284/genomic-profiling-of-er-breast-cancers-after-short-term-estrogen-suppression-reveals-alterations-associated-with-endocrine-resistance
#6
Jennifer M Giltnane, Katherine E Hutchinson, Thomas P Stricker, Luigi Formisano, Christian D Young, Monica V Estrada, Mellissa J Nixon, Liping Du, Violeta Sanchez, Paula Gonzalez Ericsson, Maria G Kuba, Melinda E Sanders, Xinmeng J Mu, Eliezer M Van Allen, Nikhil Wagle, Ingrid A Mayer, Vandana Abramson, Henry Gόmez, Monica Rizzo, Weiyi Toy, Sarat Chandarlapaty, Erica L Mayer, Jason Christiansen, Danielle Murphy, Kerry Fitzgerald, Kai Wang, Jeffrey S Ross, Vincent A Miller, Phillip J Stephens, Roman Yelensky, Levi Garraway, Yu Shyr, Ingrid Meszoely, Justin M Balko, Carlos L Arteaga
Inhibition of proliferation in estrogen receptor-positive (ER(+)) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER(+)/human epidermal growth factor receptor 2-negative (HER2(-)) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance...
August 9, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28792531/correction-preparation-of-a-novel-antiserum-to-aromatase-with-high-affinity-and-specificity-its-clinicopathological-significance-on-breast-cancer-tissue
#7
Naoki Kanomata, Shiro Matsuura, Tsunehisa Nomura, Junichi Kurebayashi, Taisuke Mori, Jo Kitawaki, Takuya Moriya
[This corrects the article DOI: 10.1371/journal.pone.0177439.].
2017: PloS One
https://www.readbyqxmd.com/read/28776988/comprehensive-and-automated-linear-interaction-energy-based-binding-affinity-prediction-for-multifarious-cytochrome-p450-aromatase-inhibitors
#8
Marc van Dijk, Antonius Ter Laak, Joerg Wichard, Luigi Capoferri, Nico P E Vermeulen, Daan P Geerke
Cytochrome P450 aromatase (CYP19A1) plays a key role in the development of estrogen dependent breast cancer and aromatase inhibitors have been at the front line of treatment for the past three decades. The development of potent, selective and safer inhibitors is ongoing with in-silico screening methods playing a more prominent role in the search for promising lead compounds in bioactivity-relevant chemical space. Here we present a set of comprehensive binding affinity prediction models for CYP19A1 using our automated Linear Interaction Energy (LIE) based workflow on a set of 132 putative and structurally diverse aromatase inhibitors obtained from a typical industrial screening study...
August 4, 2017: Journal of Chemical Information and Modeling
https://www.readbyqxmd.com/read/28770449/randomized-trial-of-vitamin-d3-to-prevent-worsening-of-musculoskeletal-symptoms-in-women-with-breast-cancer-receiving-adjuvant-letrozole-the-vital-trial
#9
Qamar J Khan, Bruce F Kimler, Pavan S Reddy, Priyanka Sharma, Jennifer R Klemp, Jennifer L Nydegger, Hung-Wen Yeh, Carol J Fabian
PURPOSE: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) frequently occur in women being treated for breast cancer. Prior studies suggest high prevalence of vitamin D deficiency in breast cancer patients with musculoskeletal (MS) pain. We conducted a randomized, placebo-controlled trial to determine if 30,000 IU vitamin D3 per week (VitD3) would prevent worsening of AIMSS in women starting adjuvant letrozole for breast cancer. METHODS: Women with stage I-III breast cancer starting adjuvant letrozole and 25(OH)D level ≤40 ng/ml were eligible...
August 2, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28766132/prognostic-and-predictive-importance-of-the-estrogen-receptor-coactivator-aib1-in-a-randomized-trial-comparing-adjuvant-letrozole-and-tamoxifen-therapy-in-postmenopausal-breast-cancer-the-danish-cohort-of-big-1-98
#10
S Alkner, M-B Jensen, B B Rasmussen, P-O Bendahl, M Fernö, L Rydén, H Mouridsen
PURPOSE: To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive breast cancer. METHOD: AIB1 was analyzed with immunohistochemistry in tissue microarrays of the Danish subcohort (N = 1396) of the International Breast Cancer Study Group's trial BIG 1-98 (randomization between adjuvant tamoxifen versus letrozole versus the sequence of the two drugs)...
August 1, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28764603/luteininzing-hormone-releasing-hormones-analogs-in-combination-with-tamoxifen-for-the-adjuvant-treatment-of-premenopausal-women-with-hormone-receptor-positive-breast-cancer
#11
Benedetta Conte, Francesca Poggio, Lucia Del Mastro
The role of ovarian function suppression (OFS) through luteinizing hormone-releasing hormone agonists (LHRHa) in addition to tamoxifen has been questioned until recently. In 2015, two large clinical trials led to a paradigm shift in the adjuvant endocrine treatment of premenopausal women, introducing the use of LHRHa plus tamoxifen (or aromatase inhibitor, AI) into current clinical practice. Areas covered: The present review aims to provide an in-depth overview of the role of LHRHa+tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer (HR+BC)...
August 10, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28759385/physical-activity-sedentary-behaviour-diet-and-cancer-an-update-and-emerging-new-evidence
#12
REVIEW
Jacqueline Kerr, Cheryl Anderson, Scott M Lippman
The lifestyle factors of physical activity, sedentary behaviour, and diet are increasingly being studied for their associations with cancer. Physical activity is inversely associated with and sedentary behaviour is positively (and independently) associated with an increased risk of more than ten types of cancer, including colorectal cancer (and advanced adenomas), endometrial cancers, and breast cancer. The most consistent dietary risk factor for premalignant and invasive breast cancer is alcohol, whether consumed during early or late adult life, even at low levels...
August 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28755088/adjuvant-endocrine-monotherapy-for-postmenopausal-early-breast-cancer-patients-with-hormone-receptor-positive-a-systemic-review-and-network-meta-analysis
#13
REVIEW
Zhu Yu, Xiaojing Guo, Yicheng Jiang, Lei Teng, Jinwu Luo, Pengfei Wang, Yunsheng Liang, Haitian Zhang
BACKGROUND: In patients with hormone receptor-positive postmenopausal of early stage breast cancer, adjuvant endocrine monotherapies include letrozole, anastrozole, exemestane, toremifene and tamoxifen. But the optimum regimen remains controversial. METHODS: PubMed, Cochrane Database and ClinicalTrials.gov were systematically reviewed of abstract for randomized-controlled trials (RCTs) to assess the efficacy of tamoxifen, letrozole, exemestane, anastrozle and toremifene for postmenopausal patients with hormone-receptor positive (HR+), who have not received prior therapy for early stage breast cancer...
July 28, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28744736/management-of-bone-health-in-postmenopausal-women-on-aromatase-inhibitors-ais-a-single-health-care-system-experience
#14
Douglas Tremblay, Vaibhav Patel, Kenneth M Fifer, Jessica Caro, Olivia Kolodka, John Mandelli, Charles L Shapiro
INTRODUCTION: Aromatase inhibitors (AIs) are the preferred therapy for postmenopausal women with early-stage estrogen receptor-positive breast cancers. However, their use causes bone loss and increased risks of osteoporosis and fractures. METHODS: This is a retrospective review of all postmenopausal women with breast cancer diagnosed and treated with AI between 2010 and 2015. Of the 564 women identified, 319 were eligible. RESULTS: The median age at AI initiation was 65 years (range 51-85 years), and the median duration of AI therapy was 28 months (1-72 months)...
July 26, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28742191/high-progesterone-levels-during-the-luteal-phase-related-to-the-use-of-an-aromatase-inhibitor-in-breast-cancer-patients
#15
C Alviggi, R Marci, R Vallone, A Conforti, F Di Rella, I Strina, S Picarelli, P De Rosa, M De Laurentiis, C Yding Andersen, G De Placido
OBJECTIVE: To evaluate the hormonal profile in three breast cancer patients who underwent controlled ovarian stimulation in the presence of the aromatase inhibitor letrozole. PATIENTS AND METHODS: In IVF University referral center, a case series of three breast cancer patients who underwent controlled ovarian stimulation (COS) with recombinant FSH and letrozole were investigated. Ovulation was induced with hCG (case No. 1) or with GnRH agonist (case No. 2-3). The primary outcome of our study was the detection of progesterone levels in the luteal phase...
July 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28739702/anastrozole-induced-autoimmune-hepatitis-a-rare-complication-of-breast-cancer-therapy
#16
Oleksandra Klapko, Elie Ghoulam, Shriram Jakate, Sheila Eswaran, Lydia Usha
BACKGROUND: Autoimmune hepatitis (AIH) is an extremely rare complication of anastrozole therapy. It presents with elevated liver function tests. The diagnosis is established by detecting high titers of autoantibodies such as antinuclear antibodies, anti-smooth muscle antibodies, and elevated immunoglobulins. It is confirmed with a liver biopsy showing interface rosetting and an increased number of plasma cells. Early diagnosis of anastrozole-induced AIH is important because it allows anastrozole to be discontinued and immunomodulatory treatment to be promptly initiated...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28730338/jagged1-promotes-aromatase-inhibitor-resistance-by-modulating-tumor-associated-macrophage-differentiation-in-breast-cancer-patients
#17
Hang Liu, Jingxuan Wang, Minghui Zhang, Qijia Xuan, Zhipeng Wang, Xin Lian, Qingyuan Zhang
PURPOSE: Endocrine resistance limits the efficacy of anti-estrogen therapies. Notch signaling is involved in modulating tumor-associated macrophage (TAM) differentiation and is upregulated in endocrine-resistant breast cancer cells. Here, we analyzed the role of Jagged1 in the regulation of TAM polarization to investigate whether the Jagged1-Notch pathway promotes the acquisition of aromatase inhibitor (AI) resistance by upregulating TAM infiltration. METHODS: The Jagged1 expression levels and M2 TAM infiltration density, in 203 tumor samples from ER-positive postmenopausal patients, who received AI treatment, were evaluated by immunohistochemical staining and the results were compared with clincopathological parameters and survival...
July 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28727878/concerns-about-methodology-of-a-trial-investigating-vaginal-health-during-aromatase-inhibitor-therapy-for-breast-cancer
#18
Per Eystein Lønning
No abstract text is available yet for this article.
August 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28727874/concerns-about-methodology-of-a-trial-investigating-vaginal-health-during-aromatase-inhibitor-therapy-for-breast-cancer-reply
#19
Michelle E Melisko, Jimmy Hwang, Hope S Rugo
No abstract text is available yet for this article.
August 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28727870/concerns-about-methodology-of-a-trial-investigating-vaginal-health-during-aromatase-inhibitor-therapy-for-breast-cancer
#20
V Craig Jordan
No abstract text is available yet for this article.
August 1, 2017: JAMA Oncology
keyword
keyword
48353
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"